Glutamate receptors in laryngeal cancer cells

Anticancer Research

Volumn 31, Issue 2, 2011, Pages 565-573

  Stepulak, Andrzej ^a,f   Luksch, Hella ^b   Uckermann, Ortrud ^b   Sifringer, Marco ^c   Rzeski, Wojciech ^d,e   Polberg, Krzysztof ^f   Kupisz, Krzysztof ^g   Klatka, Janusz ^a   Kiełbus, Michał ^a   Grabarska, Aneta ^a   Marzahn, Jenny ^b   Turski, Lechoslaw ^h   Ikonomidou, Chrysanthy ^i,j  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d MARIA CURIE SK ODOWSKA UNIVERSITY   (Poland)

^e INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

^f Ministry of Interior and Administration Republic of Poland Central Clinical Hospital   (Poland)

^g Jan Bozy District Hospital   (Poland)

^h Solvay Pharmaceuticals Inc   (Netherlands)

ⁱ UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^j UNIVERSITY OF WISCONSIN MADISON   (United States)

more..

Author keywords

Antagonist; ERK1 2 kinase; Glutamate receptor; Laryngeal cancer; Proliferation

Indexed keywords

1 (4 AMINOPHENYL) 4 METHYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; 1 (4' AMINOPHENYL) 3,5 DIHYDRO 7,8 DIMETHOXY 4H 2,3 BENZODIAZEPIN 4 ONE; 2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 6 AMINO N CYCLOHEXYL N 3 DIMETHYLTHIAZOLO[3,2 A]BENZIMIDAZOLE 2 CARBOXAMIDE; AMPA RECEPTOR ANTAGONIST; CFM 2; DIZOCILPINE; GLUTAMATE RECEPTOR 1; GLUTAMATE RECEPTOR 2; GLUTAMATE RECEPTOR 4; GLUTAMATE RECEPTOR 5; GLUTAMATE RECEPTOR 6; GLUTAMATE RECEPTOR ANTAGONIST; MEMANTINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; UNCLASSIFIED DRUG; YM 298198;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; INTRACELLULAR SIGNALING; LARYNX CARCINOMA; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA;

BENZODIAZEPINES; CARCINOMA, SQUAMOUS CELL; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DIZOCILPINE MALEATE; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; LARYNGEAL NEOPLASMS; MEMANTINE; MICROSCOPY, CONFOCAL; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; RECEPTORS, IONOTROPIC GLUTAMATE; RECEPTORS, METABOTROPIC GLUTAMATE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 79953248410     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Chu EA and Kim YJ: Laryngeal cancer: diagnosis and preoperative work-up. Otolaryngol Clin North Am 41: 673-695, 2008. (Pubitemid 351836078)
2. Cosetti M, Yu GP and Schantz SP: Five-year survival rates and time trends of laryngeal cancer in the US population. Arch Otolaryngol Head Neck Surg 134: 370-379, 2008. (Pubitemid 351581084)
3. Colevas AD: Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 24: 2644-2652, 2006.
4. Cohen EE: Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 24: 2659-2665, 2006.
5. Skerry TM and Genever PG: Glutamate signalling in non-neuronal tissues. Trends Pharmacol Sci 22: 174-181, 2001. (Pubitemid 32244303)
6. Hinoi E, Takarada T, Ueshima T, Tsuchihashi Y and Yoneda Y: Glutamate signaling in peripheral tissues. Eur J Biochem 271: 1-13, 2004. (Pubitemid 38122160)
7. Ye ZC and Sontheimer H: Glioma cells release excitotoxic concentrations of glutamate. Cancer Res 59: 4383-4391, 1999.
8. Takano T, Lin JH, Arcuino G, Gao Q, Yang J and Nedergaard M: Glutamate release promotes growth of malignant gliomas. Nat Med 7: 1010-1015, 2001. (Pubitemid 32937380)
9. Ishiuchi S, Tsuzuki K, Yoshida Y, Yamada N, Hagimura N, Okado H, Miwa A, Kurihara H, Nakazato Y, Tamura M, Sasaki T and Ozawa S: Blockage of Ca(2+)-permeable AMPA receptors suppresses migration and induces apoptosis in human glioblastoma cells. Nat Med 8: 971-978, 2002. (Pubitemid 35033701)
10. Rzeski W, Turski L and Ikonomidou C: Glutamate antagonists limit tumor growth. Proc Natl Acad Sci USA 98: 6372-6377, 2001. (Pubitemid 32488244)
11. Gerber U, Gee CE and Benquet P: Metabotropic glutamate receptors: intracellular signaling pathways. Curr Opin Pharmacol 7: 56-61, 2007. (Pubitemid 46238032)
12. Nicoletti F, Arcella A, Iacovelli L, Battaglia G, Giangaspero F and Melchiorri D: Metabotropic glutamate receptors: New targets for the control of tumor growth? Trends Pharmacol Sci 28: 206-213, 2007.
13. Kew JN and Kemp JA: Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology (Berl) 179: 4-29, 2005. (Pubitemid 40576690)
14. Palmer CL, Cotton L and Henley JM: The molecular pharmacology and cell biology of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors. Pharmacol Rev 57: 253-277, 2005. (Pubitemid 41043886)
15. Popescu G: Mechanism-based targeting of NMDA receptor functions. Cell Mol Life Sci 62: 2100-2111, 2005.
16. Aronica E, Yankaya B, Jansen GH, Leenstra S, van Veelen CW, Gorter JA and Troost D: Ionotropic and metabotropic glutamate receptor protein expression in glioneuronal tumours from patients with intractable epilepsy. Neuropathol Appl Neurobiol 27: 223-237, 2001. (Pubitemid 32678675)
17. de Groot JF, Piao Y, Lu L, Fuller GN and Yung WK: Knockdown of GluR1 expression by RNA interference inhibits glioma proliferation. J Neurooncol 88: 121-133, 2008.
18. Chang HJ, Yoo BC, Lim SB, Jeong SY, Kim WH and Park JG: Metabotropic glutamate receptor 4 expression in colorectal carcinoma and its prognostic significance. Clin Cancer Res 11: 3288-3295, 2005. (Pubitemid 40627877)
19. Yoo BC, Jeon E, Hong SH, Shin YK, Chang HJ and Park JG: Metabotropic glutamate receptor 4-mediated 5-fluorouracil resistance in a human colon cancer cell line. Clin Cancer Res 10: 4176-4184, 2004. (Pubitemid 38812498)
20. Liu JW, Kim MS, Nagpal J, Yamashita K, Poeta L, Chang X, Lee J, Park HL, Jeronimo C, Westra WH, Mori M, Moon C, Trink B and Sidransky D: Quantitative hypermethylation of NMDAR2B in human gastric cancer. Int J Cancer 121: 1994-2000, 2007.
21. Abdul M and Hoosein N: N-Methyl-D-aspartate receptor in human prostate cancer. J Membr Biol 205: 125-128, 2005. (Pubitemid 41803689)
22. Pissimissis N, Papageorgiou E, Lembessis P, Armakolas A and Koutsilieris M: The glutamatergic system expression in human PC-3 and LNCaP prostate cancer cells. Anticancer Res 29: 371-377, 2009.
23. Marin YE and Chen S: Involvement of metabotropic glutamate receptor 1, a G protein coupled receptor, in melanoma development. J Mol Med 82: 735-749, 2004. (Pubitemid 40022267)
24. Kalariti N, Lembessis P and Koutsilieris M: Characterization of the glutametergic system in MG-63 osteoblast-like osteosarcoma cells. Anticancer Res 24: 3923-3929, 2004. (Pubitemid 40468687)
25. Park SY, Lee SA, Han IH, Yoo BC, Lee SH, Park JY, Cha IH, Kim J and Choi SW: Clinical significance of metabotropic glutamate receptor 5 expression in oral squamous cell carcinoma. Oncol Rep 17: 81-87, 2007.
26. Stepulak A, Luksch H, Gebhardt C, Uckermann O, Marzahn J, Sifringer M, Rzeski W, Staufner C, Brocke KS, Turski L and Ikonomidou C: Expression of glutamate receptor subunits in human cancers. Histochem Cell Biol 132: 435-445, 2009.
27. Rzeski W, Paduch R, Klatka J, Kandefer-Szerszen M, Stepulak A, Pozarowski P and Zdzisinska B: Establishment and preliminary characterization of two cell lines derived from larynx carcinoma. Folia Histochem Cytobiol 40: 195-196, 2002. (Pubitemid 34477146)
28. Stepulak A, Sifringer M, Rzeski W, Endesfelder S, Gratopp A, Pohl EE, Bittigau P, Felderhoff-Mueser U, Kaindl AM, Buhrer C, Hansen HH, Stryjecka-Zimmer M, Turski L and Ikonomidou C: NMDA antagonist inhibits the extracellular signal-regulated kinase pathway and suppresses cancer growth. Proc Natl Acad Sci USA 102: 15605-15610, 2005. (Pubitemid 41528103)
29. Stepulak A, Sifringer M, Rzeski W, Brocke K, Gratopp A, Pohl EE, Turski L and Ikonomidou C: AMPA antagonists inhibit the extracellular signal-regulated kinase pathway and suppress lung cancer growth. Cancer Biol Ther 6: 1908-1915, 2007.
30. Kalariti N, Pissimissis N and Koutsilieris M: The glutamatergic system outside the CNS and in cancer biology. Expert Opin Investig Drugs 14: 1487-1496, 2005. (Pubitemid 41749194)
31. Watanabe K, Kanno T, Oshima T, Miwa H, Tashiro C and Nishizaki T: The NMDA receptor NR2A subunit regulates proliferation of MKN45 human gastric cancer cells. Biochem Biophys Res Commun 367: 487-490, 2008.
32. Ohtani Y, Harada T, Funasaka Y, Nakao K, Takahara C, Abdel-Daim M, Sakai N, Saito N, Nishigori C and Aiba A: Metabotropic glutamate receptor subtype-1 is essential for in vivo growth of melanoma. Oncogene 27: 7162-7170, 2008.
33. Beretta F, Bassani S, Binda E, Verpelli C, Bello L, Galli R and Passafaro M: The GluR2 subunit inhibits proliferation by inactivating Src-MAPK signalling and induces apoptosis by means of caspase 3/6-dependent activation in glioma cells. Eur J Neurosci 30: 25-34, 2009.
34. Choi SW, Park SY, Hong SP, Pai H, Choi JY and Kim SG: The expression of NMDA receptor 1 is associated with clinicopathological parameters and prognosis in the oral squamous cell carcinoma. J Oral Pathol Med 33: 533-537, 2004. (Pubitemid 39318463)
35. Grossman SA, Ye X, Chamberlain M, Mikkelsen T, Batchelor T, Desideri S, Piantadosi S, Fisher J and Fine HA: Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial. J Clin Oncol 27: 4155-4161, 2009.